Nimrata Hunt's most recent trade in Idexx Laboratories, Inc. was a trade of 1,758 Common Stock done at an average price of $634.6 . Disclosure was reported to the exchange on March 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Sale of securities on an exchange or to another person at price $ 634.57 per share. | 03 Mar 2026 | 1,758 | 18,140 (0%) | 0% | 634.6 | 1,115,577 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Sale of securities on an exchange or to another person at price $ 661.54 per share. | 26 Feb 2026 | 2,693 | 19,898 (0%) | 0% | 661.5 | 1,781,531 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 4,625 | 4,625 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 1,620 | 1,620 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 1,508 | 23,378 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 1,508 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 629.35 per share. | 12 Feb 2026 | 1,154 | 22,591 (0%) | 0% | 629.4 | 726,270 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 1,094 | 1,094 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 367 | 23,745 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 367 | 1,101 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 301 | 602 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 301 | 21,870 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 207 | 21,569 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 207 | 207 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 204 | 21,362 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 204 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 162 | 162 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 288.78 per share. | 07 Nov 2025 | 7,125 | 25,168 (0%) | 0% | 288.8 | 2,057,558 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2025 | 7,125 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2025 | 5,405 | 1,604 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 505.53 per share. | 07 Nov 2025 | 5,405 | 30,573 (0%) | 0% | 505.5 | 2,732,390 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Sale of securities on an exchange or to another person at price $ 702.20 per share. | 07 Nov 2025 | 5,114 | 25,459 (0%) | 0% | 702.2 | 3,591,059 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Sale of securities on an exchange or to another person at price $ 704.87 per share. | 07 Nov 2025 | 1,468 | 22,526 (0%) | 0% | 704.9 | 1,034,743 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Sale of securities on an exchange or to another person at price $ 703.73 per share. | 07 Nov 2025 | 1,465 | 23,994 (0%) | 0% | 703.7 | 1,030,970 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Sale of securities on an exchange or to another person at price $ 705.54 per share. | 07 Nov 2025 | 1,378 | 21,148 (0%) | 0% | 705.5 | 972,241 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Sale of securities on an exchange or to another person at price $ 656.53 per share. | 11 Aug 2025 | 1,200 | 16,806 (0%) | 0% | 656.5 | 787,840 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 178.26 per share. | 11 Aug 2025 | 560 | 17,366 (0%) | 0% | 178.3 | 99,826 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 560 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 483 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 206.94 per share. | 11 Aug 2025 | 483 | 17,849 (0%) | 0% | 206.9 | 99,952 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 183 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 544.08 per share. | 11 Aug 2025 | 183 | 18,032 (0%) | 0% | 544.1 | 99,567 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2025 | 5,865 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 178.26 per share. | 06 Aug 2025 | 5,865 | 19,438 (0%) | 0% | 178.3 | 1,045,495 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2025 | 5,711 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 206.94 per share. | 06 Aug 2025 | 5,711 | 25,149 (0%) | 0% | 206.9 | 1,181,834 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Sale of securities on an exchange or to another person at price $ 629.87 per share. | 06 Aug 2025 | 3,018 | 22,131 (0%) | 0% | 629.9 | 1,900,933 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Sale of securities on an exchange or to another person at price $ 630.91 per share. | 06 Aug 2025 | 2,907 | 19,224 (0%) | 0% | 630.9 | 1,834,052 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Sale of securities on an exchange or to another person at price $ 630.69 per share. | 06 Aug 2025 | 1,218 | 18,006 (0%) | 0% | 630.7 | 768,179 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2025 | 1,218 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 141.60 per share. | 06 Aug 2025 | 1,218 | 13,573 (0%) | 0% | 141.6 | 172,469 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 6,320 | 6,320 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 1,468 | 1,468 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 301 | 903 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 301 | 12,595 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 444.53 per share. | 13 Feb 2025 | 268 | 12,327 (0%) | 0% | 444.5 | 119,134 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 217 | 217 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 207 | 414 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 207 | 12,294 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 204 | 204 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 204 | 12,087 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 160 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 160 | 11,883 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Hunt Nimrata | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 5,407 | 5,407 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Hunt Nimrata | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 1,204 | 1,204 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Hunt Nimrata | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 560.56 per share. | 14 Feb 2024 | 263 | 11,676 (0%) | 0% | 560.6 | 147,427 | Common Stock |
| Idexx Laboratories | Hunt Nimrata | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 208 | 621 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 208 | 11,939 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 204 | 408 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 204 | 11,731 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Hunt Nimrata | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 178 | 178 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 173 | 11,366 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Hunt Nimrata | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 173 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 161 | 11,527 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Hunt Nimrata | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 161 | 160 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Hunt Nimrata | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 126 | 11,193 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Hunt Nimrata | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 126 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 503.65 per share. | 14 Feb 2023 | 239 | 11,015 (0%) | 0% | 503.6 | 120,372 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 204 | 3,569 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 204 | 11,254 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 173 | 10,889 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 173 | 3,934 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 161 | 11,050 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 161 | 3,773 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 127 | 10,716 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 127 | 4,107 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 126 | 10,589 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 126 | 4,234 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 5,868 | 5,868 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 1,508 | 3,531 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 829 | 4,360 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2023 | 706 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 141.60 per share. | 08 Feb 2023 | 706 | 10,463 (0%) | 0% | 141.6 | 99,970 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 201 | 201 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 7,009 | 7,009 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 816 | 2,698 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 505.53 per share. | 14 Feb 2022 | 204 | 9,702 (0%) | 0% | 505.5 | 103,128 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 197 | 197 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 173 | 2,184 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 173 | 9,745 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 161 | 9,906 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 161 | 2,023 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 127 | 9,572 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 127 | 2,357 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 126 | 9,445 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 126 | 2,484 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 88 | 9,319 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 88 | 2,610 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 769 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.85 per share. | 10 Aug 2021 | 769 | 8,875 (0%) | 0% | 67.9 | 52,177 | Common Stock |
| Idexx Laboratories | Nimrata Hunt | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 141.60 per share. | 10 Aug 2021 | 337 | 9,212 (0%) | 0% | 141.6 | 47,719 | Common Stock |